![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, April 21, 2013 10:36:46 AM
Quote:
"Second, Gerald has stuck to his guns by moving ahead with delivery of MANF using CED and micro catheters versus viral vectors. Expect a jv with nsGene or similar company that uses microcathters".
Dr Jerry: I so appreciate your continued support and feedback. I just want to make sure that things are put in perspective. If AMBS partners with nsGene (or similar company)...I am doubtful if that it the type of JV that most of us are looking for....it appears to be a drug delivery partnership. I believe most are looking for a Pharma. partner that will infuse a large chunk of cash up front to fund MANF trials. In summary, what you have shared and outlined would be considered a huge success and big gain to enhance our MANF drug delivery mechanism.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM